CIGNA PRECISION MEDICINE CLINICAL POLICY

Dr. Jeffrey Langsam Cigna Market Medical Executive – Connecticut Market

January 23, 2019

Offered by Cigna Health and Life Insurance Company or its affiliates

Together, all the way."







- The cost to draft a whole human genome sequence:
 - 2006: \$14,000,000
 - 2015: \$4,000
 - 2018: less than \$1,000



https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost

Confidential, unpublished property of Cigna. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2020 Cigna

Cigna Clinical Policy



- Considerable interest in developing policy in 2012 with BRCA testing becoming mainstream.
- Created a partnership with InformedDNA to inform precision medicine policy and guide clinical determinations.
- InformedDNA provides competencies, genetic counselors and offers research for coverage policy.



Cigna Clinical Policy – continued



- As part of the precision medicine policy, Cigna requires that genetic counseling be done pre and post testing.
- The genetic counselor must be independent, not affiliated with the lab performing testing.
- Counseling can be completed by the ordering provider.
- If the genetic counselor agrees that testing is appropriate, testing will be approved by Cigna even if the request does not satisfy medical necessity guidelines.
- Counseling can be completed in person or telephonically within 24-48 hours.



Cigna Clinical Policy – continued



- Goals of Cigna's precision medicine clinical policy include:
 - Ensuring patients receive appropriate testing.
 - Necessary follow-up.
 - A clearly defined plan of care.



Confidential, unpublished property of Cigna. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2020 Cigna

Cigna Clinical Policy – continued



- Potential concerns:
 - Given the rapid advancement of precision medicine, many tests exist without a clear understanding of what to do with the results.
 - Other concerns include subjecting patients to unnecessary subsequent tests, invasive procedures, anxiety and costs.



Future Directions



- Prenatal testing continues to advance, no genetic counseling required.
- Molecular Profiling many cancers with increased understanding of tumor drivers.
- Pharmacogenomics no screening approval currently, but continuing to assess.



All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company or its affiliates. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

01/20 © 2020 Cigna. Some content provided under license.



Confidential, unpublished property of Cigna. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2020 Cigna